EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Bispecific antibodies in lung cancer: From molecular engineering to clinical breakthroughs and translational challenges

Zhiyu Liu, Yang Zhang, Man Xue, Zhaoxia Wang

Cancer Treatment Reviews · 2026-11 · 150 · 103203

DOI: 10.1016/j.ctrv.2026.103203 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2026-11. Verfasst von Zhiyu Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Lung Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Jiangsu Province, Nanjing Medical University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificLung NeoplasmsAntineoplastic Agents, ImmunologicalHumansTumor MicroenvironmentImmunotherapyAnimals

Stichwörter der Autor:innen

Bispecific antibodiesClinical toxicityImmunotherapy resistanceLung cancerTumor microenvironment

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR China.
  • Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR China. Electronic address: wangzhaoxia@njmu.edu.cn.

Förderung

  • Natural Science Foundation of Jiangsu Province
  • Nanjing Medical University
  • National Natural Science Foundation of China

Zitieren

APA

Liu, Z., Zhang, Y., Xue, M., & Wang, Z. (2026). Bispecific antibodies in lung cancer: From molecular engineering to clinical breakthroughs and translational challenges. Cancer Treatment Reviews, 150, 103203. https://doi.org/10.1016/j.ctrv.2026.103203

Vancouver

Liu Z, Zhang Y, Xue M, Wang Z. Bispecific antibodies in lung cancer: From molecular engineering to clinical breakthroughs and translational challenges. Cancer Treatment Reviews. 2026;150:103203. doi:10.1016/j.ctrv.2026.103203

BibTeX
@article{Liu2026,
  author = {Liu, Zhiyu and Zhang, Yang and Xue, Man and Wang, Zhaoxia},
  title = {Bispecific antibodies in lung cancer: From molecular engineering to clinical breakthroughs and translational challenges},
  journal = {Cancer Treatment Reviews},
  year = {2026},
  volume = {150},
  pages = {103203},
  doi = {10.1016/j.ctrv.2026.103203}
}
Kostenlos starten →